China Biotech Services Holdings Limited provided consolidated earnings guidance for the year ended 31 December 2023. For the period, Group expected to record a net loss attributable to the owners of the Company of approximately HKD 90,000,000. In contrast to the Loss, the Group recorded a net profit attributable to the owners of the Company of approximately HKD 258,087,000 for the corresponding period in 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.375 HKD | +1.35% | +25.42% | -51.95% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.95% | 41.91M | |
+17.18% | 85.55B | |
-28.48% | 70.07B | |
+6.76% | 28.95B | |
-7.44% | 17.51B | |
+2.14% | 17.39B | |
+2.10% | 15.38B | |
+7.02% | 13.4B | |
+64.96% | 12.93B | |
+6.64% | 12.77B |
- Stock Market
- Equities
- 8037 Stock
- News China Biotech Services Holdings Limited
- China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023